ABOS Stock Overview
A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Acumen Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.85 |
| 52 Week High | US$6.60 |
| 52 Week Low | US$1.81 |
| Beta | 0.11 |
| 11 Month Change | -11.76% |
| 3 Month Change | -16.18% |
| 1 Year Change | -56.15% |
| 33 Year Change | -83.44% |
| 5 Year Change | n/a |
| Change since IPO | -85.82% |
Recent News & Updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05
Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Shareholder Returns
| ABOS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 13.3% | 4.7% | 3.1% |
| 1Y | -56.2% | 15.1% | 24.9% |
Return vs Industry: ABOS underperformed the US Biotechs industry which returned 14.9% over the past year.
Return vs Market: ABOS underperformed the US Market which returned 25.4% over the past year.
Price Volatility
| ABOS volatility | |
|---|---|
| ABOS Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ABOS's share price has been volatile over the past 3 months.
Volatility Over Time: ABOS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 52 | Dan O'Connell | acumenpharm.com |
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug.
Acumen Pharmaceuticals, Inc. Fundamentals Summary
| ABOS fundamental statistics | |
|---|---|
| Market cap | US$170.03m |
| Earnings (TTM) | -US$64.86m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs ABOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABOS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$56.45m |
| Gross Profit | -US$56.45m |
| Other Expenses | US$8.41m |
| Earnings | -US$64.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 12.0% |
How did ABOS perform over the long term?
See historical performance and comparison